Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform

Establishes co-development and co-commercialization agreement on Foghorn's selective BRM program and an additional undisclosed program Collaboration includes three additional discovery programs Foghorn to receive $300 million upfront and an equity investment by Lilly of $80 million at $20 per share